Literature DB >> 15500558

Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?

S-N Lu1, H-D Tung, T-M Chen, C-M Lee, J-H Wang, C-H Hung, C-H Chen, C-S Changchien.   

Abstract

The diagnosis of acute hepatitis C virus (HCV) infection relies on documented positive-seroconversion of HCV antibody (anti-HCV). Because of the detection of seroconversion at an earlier stage by second or third generation anti-HCV enzyme immunoassays (EIA), the diagnosis of acute hepatitis C (AHC) may be underestimated. The aim of this study was to evaluate whether rising anti-HCV titre could be used to diagnose AHC or not. Eighteen patients with a clinical diagnosis of acute hepatitis C were enrolled, including eight cases with documented seroconversion to anti-HCV and 10 cases with clinically suspected acute hepatitis C. Four chronic hepatitis C patients with acute exacerbation were selected as a control group. Serial sera were assayed with a third generation anti-HCV (AxSYM, version 3.0; Abbott, Chicago, IL, USA) and recombinant immunoblot assays (RIBA; Chiron HCV 3.0 Strip; Immunoblot, Emeryville, CA, USA) and the titre of anti-HCV expressed as signal/cutoff (S/CO) ratio and the RIBA patterns were correlated. Seven of eight documented AHC (one lacking the initial serum) and five of 10 clinically suspected AHC showed a rising pattern of S/CO values. The initial S/CO values on the first visit were less than 40 in 14 of 18 cases. The RIBA pattern shifted from negative/indeterminate to positive in five of seven documented AHC and 4 of 10 clinically suspected AHC cases. Fifteen of 18 cases had seroconversions of at least one antibody, whilst 85.7% showed a rising S/CO ratio. On the contrary, the S/CO ratio and RIBA pattern remained unaltered in chronic hepatitis C with acute exacerbation. The rise in S/CO was usually accompanied with an increase in the number of RIBA reactive bands and their intensity in acute hepatitis C patients. The rise in S/CO ratios using a third generation anti-HCV assay and the RIBA pattern might be used as a supplemental diagnostic criterion for acute HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15500558     DOI: 10.1111/j.1365-2893.2004.00533.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

Review 1.  Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Rosa Zampino; Margherita Macera; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.

Authors:  E Sagnelli; T Santantonio; N Coppola; M Fasano; M Pisaturo; C Sagnelli
Journal:  Infection       Date:  2014-03-12       Impact factor: 3.553

3.  Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.

Authors:  Lia L Lewis-Ximenez; Georg M Lauer; Julian Schulze Zur Wiesch; Paulo Sergio Fonseca de Sousa; Cleber F Ginuino; Gláucia Paranhos-Baccalá; Hanno Ulmer; Karl P Pfeiffer; Georg Goebel; João Luiz Pereira; Jaqueline Mendes de Oliveira; Clara Fumiko Tachibana Yoshida; Elisabeth Lampe; Carlos Eduardo Velloso; Marcelo Alves Pinto; Henrique Sergio Coelho; Adilson José Almeida; Carlos Augusto Fernandes; Arthur Y Kim; Alexander M Strasak
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

4.  Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.

Authors:  Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

5.  Is hepatitis C virus core antigen an adequate marker for community screening?

Authors:  Yuan-Hung Kuo; Kuo-Chin Chang; Jing-Houng Wang; Pei-Shan Tsai; Shu-Feng Hung; Chao-Hung Hung; Chien-Hung Chen; Sheng-Nan Lu
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

6.  Distinguishing acute from chronic and resolved hepatitis C virus (HCV) infections by measurement of anti-HCV immunoglobulin G avidity index.

Authors:  S Klimashevskaya; A Obriadina; T Ulanova; G Bochkova; A Burkov; A Araujo; Susan L Stramer; Leslie H Tobler; Michael P Busch; Howard A Fields
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 7.  Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-11       Impact factor: 3.267

8.  Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.

Authors:  Enea Spada; Pietro Amoroso; Gloria Taliani; Ornella Zuccaro; Piergiorgio Chiriacò; Patrizia Maio; Giuseppe Maio; Maria Luisa Esposito; Corrado Mariano; Roberto Rinaldi; Pietro Bellissima; Maria Elena Tosti; Paola Del Porto; Ruggiero Francavilla; Vincenzo Mellace; Anna Rosa Garbuglia; Antonella Folgori; Alfonso Mele
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

9.  TLR7 and TLR8 gene variations and susceptibility to hepatitis C virus infection.

Authors:  Chiou-Huey Wang; Hock-Liew Eng; Kuei-Hsiang Lin; Cheng-Hsien Chang; Chi-An Hsieh; Yen-Li Lin; Tsun-Mei Lin
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

10.  Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients.

Authors:  Farahnaz Joukar; Sepiedeh Besharati; Hasan Mirpour; Fariborz Mansour-Ghanaei
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.